WASHINGTON — To the average observer, the Alzheimer’s Drug Discovery Foundation couldn’t be further from achieving its mission of finding a treatment or cure for Alzheimer’s. But the group’s executive director, Dr. Howard Fillit, tells a different story.

Despite a spate of high-profile trial failures and the present dearth of late-stage clinical development programs for the devastating disease, Fillit insists that the industry is on the cusp of some breakthroughs. He insists, in fact, that he is “very, very optimistic” that there could be new Alzheimer’s treatments approved by 2025.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.